Perhaps most importantly, inhibitors of VEGF-C/VEGF-R3 signaling, including siRNA and soluble VEGF-R3, reduce lymphangiogenesis, lymph node metastasis, and enhance survival in mouse tumor models [54–56]. Here, FLT4 is linked to neoplasm.